Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

近日，何氏眼科(301103)正式成为全国眼科联盟人工智能分联盟成员单位，这标志着何氏眼科在智慧医 疗与人工智能临床应用领域进一步融入国家级前沿创新平台，为其提升诊疗水平、增强科研创新能力提 供了重要支撑。 在深耕国内市场的同时，何氏眼科积极响应"一带一路"倡议，联合辽宁何氏医学院、何氏眼产业集团等 合作伙伴，推动中国眼科防盲技术与经验走向国际。通过人才培养、技术分享与防盲模式建设等方式， 将基于人工智能与大数据的创新筛查技术和管理模式推广至共建"一带一路"国家和地区，助力提升当地 基层眼健康服务能力，为世界提供可复制、可推广、可持续的智慧眼健康生态"中国样本"。 何氏眼科表示，公司将以加入全国眼科联盟人工智能分联盟为契机，依托联盟平台与资源优势，持续深 化产学研国际合作，拓展人工智能在各类眼科疾病筛查中的应用，推动科技创新与产业创新深度融合， 让优质眼健康服务惠及更广大基层群众，为健康中国建设和全球眼健康事业贡献力量。（燕云） 作为以创新科技为驱动、聚焦全生命周期眼健康管理的数字眼健康生态产业集团，何氏眼科以构建"智 慧光明城"为愿景，联合辽宁何氏医学院、何氏眼产业集团、眼基因库等机构，形成协同创新矩阵。集 ...

（编辑 楚丽君） 证券日报网讯 1月13日，光正眼科在互动平台回答投资者提问时表示，公司将会按照证监会、深交所的 相关规定在定期报告中披露股东人数，敬请关注公司相关公告。也可将有效持股证明文件发送至 investor@xsjyk.com，公司核实投资者身份后将予以回复。 ...

Core Insights - The article highlights the official certification of Nanjing Aier Eye Hospital as the first clinical application cooperation center for the EVO+ ICL (V5) technology, marking a significant milestone in refractive surgery in the region [1][3] - The EVO+ ICL (V5) technology is recognized for its advancements in optimizing night vision, providing patients in Jiangsu with access to cutting-edge refractive correction solutions [1][5] Group 1: Certification and Achievements - Nanjing Aier Eye Hospital received the "EVO+ ICL (V5) First Clinical Application Cooperation Center" certification and the "EVO+ ICL (V5) Certified Surgeon" certificate for its director, Xiong Juan, indicating a strong clinical capability [1][3] - The hospital's achievement reflects the strategic empowerment of the Aier Eye Group and the regional technical strength, showcasing a complete cycle from group leadership to hospital implementation [3] Group 2: Technological Advancements - The EVO+ ICL (V5) lens features a significant technological upgrade with an optical zone expanded to 6.1mm, effectively addressing night vision issues such as glare and halos for myopic patients [5] - The V5 lens allows for customized correction precision for moderate to low myopia, enhancing visual quality for patients with specific needs [5] Group 3: Clinical Practice and Expertise - Nanjing Aier Eye Hospital successfully performed Jiangsu's first EVO+ ICL (V5) implantation surgery on January 4, utilizing advanced technology such as the Zeiss ARTEVO 800 digital navigation 3D microscope for enhanced surgical precision [8] - Xiong Juan, the certified surgeon, is a leading figure in the refractive surgery department, with extensive international certifications and experience in performing thousands of refractive surgeries [9] Group 4: Community Impact and Future Plans - The dual certification is seen as a starting point for high-quality service, aiming to provide Jiangsu patients with faster and safer access to innovative refractive correction technologies [12] - Nanjing Aier Eye Hospital plans to leverage its global ophthalmic resources and local surgical platform to offer expert consultations and educational outreach, ensuring that patients with high myopia and astigmatism receive precise and safe corrective services [12][15]

Core Viewpoint - The establishment of the Traditional Chinese Medicine (TCM) Eye Clinic at Qingdao Huaxia Eye Hospital marks a significant step towards the deep integration of traditional and modern medicine, providing a more diverse, systematic, and personalized health pathway for eye disease patients [1][3]. Group 1: Hospital's Strategic Initiatives - The hospital is responding to the national call for the collaborative development of TCM and Western medicine by establishing the TCM Eye Clinic, which enhances its service offerings and meets the public's demand for integrated healthcare [3]. - The establishment of the TCM Eye Clinic is seen as a new starting point for high-quality service, with plans for clinical, research, and talent development to create a comprehensive eye health service model that integrates prevention, treatment, and rehabilitation [5]. Group 2: Leadership and Expertise - Dr. Li Qing has been appointed as the head of the TCM Eye Clinic, bringing extensive clinical experience and recognition in TCM ophthalmology, which strengthens the professional foundation and confidence in this emerging discipline [7]. Group 3: Service Offerings - The TCM Eye Clinic will focus on three main areas: 1. Providing TCM therapies for common issues such as dry eye, visual fatigue, and myopia prevention [9]. 2. Offering collaborative interventions for chronic eye diseases like age-related macular degeneration and diabetic retinopathy, combining TCM with standard Western treatments to improve symptoms and quality of life [9]. 3. Promoting eye disease prevention and health management through TCM principles, including health education and body constitution identification [9]. Group 4: Future Outlook - The hospital aims to leverage the establishment of the TCM Eye Clinic to explore innovative paths for integrating TCM and Western medicine in eye health, continuously enhancing diagnostic and service quality for the local community [11].

截至2026年1月12日收盘，何氏眼科(301103)报收于20.84元，上涨2.86%，换手率1.99%，成交量3.14万 手，成交额6458.06万元。 董秘最新回复 投资者： 请问何星儒何总，贵公司股价长期处于低位，对公司品牌带来极大负面影响，为何不积极回 购股份提升公司的市场价值呢？ 董秘： 尊敬的投资者您好，截止目前公司已累计回购股份2,722,719股。关于股份回购计划，公司管理 层将根据公司资金安排并结合实际经营情况及未来发展需求等多种因素考量，未来如有回购相关计划， 将严格按照法律法规及交易所规则，履行决策程序并及时披露相关信息。公司将继续做好经营管理，夯 实企业内在价值，坚持长期可持续发展战略、透明的信息披露与有效的投资者沟通，稳步推进资本市场 品牌建设，努力为投资者创造长期价值。谢谢！ 投资者： 董秘你好，公司长期大幅破发，投资者毫无获得感，作为辽宁地区知名企业，后续公司有什 么具体的稳定提升股价的措施吗？ 董秘： 尊敬的投资者您好，股价的波动受市场整体情绪、行业板块轮动、资金偏好等多重因素综合影 响。公司坚持聚焦主业，稳健经营，以投资者为本，通过不断完善公司治理，积极加强与国内外同领域 ...

Core Viewpoint - The company emphasizes the potential of robotics in the medical field, highlighting improvements in effectiveness, efficiency, and cost reduction, while maintaining that expert operation and patient-centered ethics are paramount [1] Group 1: Technological Advancements - The rapid development of technology is paving the way for significant advancements in medical robotics [1] - The introduction of the new generation of robotic equipment, such as the Zeiss VISUMAX800 and the SMILEpro, is planned for multiple hospitals by 2025 [1] Group 2: Operational Milestones - The Changsha Medical Center successfully performed Hunan Province's first eye surgery using a robotic-assisted technique for precise subretinal injection [1]

Core Viewpoint - The Tai'an Tongyi Ren Ophthalmology Hospital has been fined for violating medical insurance regulations, including duplicate charges and improper billing practices [1][2]. Summary by Relevant Categories Administrative Penalty - The Tai'an Medical Security Bureau issued an administrative penalty decision (Document No. Tai'an Medical Insurance Office [2025] No. 8) against the hospital [2]. - The penalty includes a fine of 39,399.48 yuan (approximately 3.94 million yuan) [1][2]. - The penalty decision date is set for December 31, 2025 [2]. Violations - The hospital was found to have engaged in multiple illegal activities, including: - Duplicate charging - Charging above standard rates - Switching diagnostic treatment items - Including non-reimbursable medical expenses in the medical insurance fund settlement [1][2]. - These actions violate the "Regulations on the Supervision and Administration of the Use of Medical Insurance Funds" [2]. Legal Basis - The penalty was based on Article 38 of the "Regulations on the Supervision and Administration of the Use of Medical Insurance Funds" and the "Shandong Province Medical Insurance Administrative Penalty Discretionary Guidelines" [2].

1月11日，深圳普瑞眼科（301239）医院举办"高清视界，不分昼夜——EVO+ ICL(V5)新品发布会"。作 为瑞士STAAR Surgical公司认证的中国内地首批EVO+ ICL(V5)临床应用合作中心，深圳普瑞眼科不仅 带来了前沿晶体技术，更展现了由"双院长、双博导"领衔的中山眼科博士团的医疗实力。 中山眼科博士团护航新技术落地 作为博士团核心成员，徐洋涛团队已于发布会前夕成功实施了院内首批EVO+ ICL(V5)晶体植入手术， 手术效果备受好评。 6.1mm大光区，直击"夜视"痛点 徐洋涛在现场解析了V5晶体的核心突破——中央光学区扩大至6.1mm。这一设计如同给眼睛换上了"更 大的镜头"，有效覆盖暗光下自然放大的瞳孔。这对视觉质量有极高要求的群体尤为重要。 发布会当天，两个不同阶段的患者分别分享术前、术后体验，全方位展示V5技术的落地全貌。王同学 是一位高校学霸，"因为经常需要熬夜查文献、做实验，我对夜间视力要求很高。了解到V5晶体的大光 区优势后，我非常心动。" 在发布会当天，王同学在深圳普瑞眼科完成了全套详细的术前检查。拿到合 格的检查报告后，他表示："检查流程非常细致，徐洋涛医生对数据的解 ...

进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为7084.28万元。该股近5个交易日累 计上涨4.01%，主力资金合计净流入6746.8万元。 责任编辑：小浪快报 1月9日，爱尔眼科收涨0.97%，收盘价为11.42元，发生1笔大宗交易，合计成交量22.1万股，成交金额 249.95万元。 第1笔成交价格为11.31元，成交22.10万股，成交金额249.95万元，溢价率为-0.96%，买方营业部为华泰 证券股份有限公司成都锦晖西二街证券营业部，卖方营业部为华泰证券股份有限公司成都锦晖西二街证 券营业部。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ ...